Related Experiment Video
Updated: May 25, 2026
08:49
A 3D Organotypic Melanoma Spheroid Skin Model
Published on: May 18, 2018
In-transit melanoma: an individualized approach
Travis E Grotz1, Aaron S Mansfield, Lisa A Kottschade
1Department of Surgery, Mayo Clinic, Rochester, Minnesota, USA.
Oncology (Williston Park, N.Y.)
|February 15, 2012
Summary
In-transit melanoma, a type of locoregional recurrence, involves lymphatic spread. This summary outlines an institutional algorithm for individualized treatment of these challenging melanoma metastases.
Area of Science:
- Oncology
- Dermatology
- Surgical Oncology
Background:
- Locoregional recurrences in melanoma commonly manifest as intradermal or subcutaneous metastases.
- In-transit melanoma involves lymphatic space contamination and offers potential for long-term cure in some patients with treatment.
- Managing in-transit melanoma is complex due to variations in lesion characteristics and biological behavior, with limited high-level evidence guiding treatment.
Purpose of the Study:
- To present an institutional treatment algorithm for managing in-transit melanoma.
- To provide a framework for individualizing treatment strategies based on patient presentation.
Main Methods:
- Development of a clinical treatment algorithm for in-transit melanoma.
- Individualization of treatment based on lesion number, depth, location, distribution, and biological behavior.
Main Results:
- The presented algorithm allows for tailored management of in-transit melanoma.
- Individualized treatment approaches are crucial given the heterogeneity of the disease.
Conclusions:
- An institutional algorithm can guide the complex management of in-transit melanoma.
- Personalized treatment strategies are essential for optimizing outcomes in patients with in-transit melanoma.
Related Concept Videos
01:30Skin Cancer
Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.